Summit Therapeutics plc (SMMT): Price and Financial Metrics

Summit Therapeutics plc (SMMT): $3.67

0.36 (-8.93%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

B

Add SMMT to Watchlist
Sign Up

SMMT Price/Volume Stats

Current price $3.67 52-week high $5.22
Prev. close $4.03 52-week low $1.30
Day low $3.63 Volume 1,361,500
Day high $4.07 Avg. volume 2,290,263
50-day MA $4.20 Dividend yield N/A
200-day MA $2.69 Market Cap 2.58B

SMMT Stock Price Chart Interactive Chart >


Summit Therapeutics plc (SMMT) Company Bio


Summit Therapeutics plc operates as a biopharmaceutical company primarily in the United Kingdom and the Unites States. It focuses on the discovery, development, and commercialization of novel medicines to treat the Duchenne Muscular Dystrophy (DMD), a fatal muscle wasting disease; and infections caused by Clostridium difficile bacteria (CDI). The company was founded in 2003 and is based in Abingdon, England.


SMMT Latest News Stream


Event/Time News Detail
Loading, please wait...

SMMT Latest Social Stream


Loading social stream, please wait...

View Full SMMT Social Stream

Latest SMMT News From Around the Web

Below are the latest news stories about SUMMIT THERAPEUTICS INC that investors may wish to consider to help them evaluate SMMT as an investment opportunity.

Insiders hold 82% of Summit Therapeutics Inc. (NASDAQ:SMMT), and they've been buying recently

Key Insights Insiders appear to have a vested interest in Summit Therapeutics' growth, as seen by their sizeable...

Yahoo | November 27, 2023

Summit Therapeutics Inc. (NASDAQ:SMMT) Q3 2023 Earnings Call Transcript

Summit Therapeutics Inc. (NASDAQ:SMMT) Q3 2023 Earnings Call Transcript November 7, 2023 Operator: Good morning, and welcome to the Summit Therapeutics Third Quarter 2023 Earnings and Update Call. All participants will be able to listen only until the question-and-answer portion of this call. We do not expect any technical difficulties today; however, in the event […]

Yahoo | November 8, 2023

Summit Therapeutics Inc (SMMT) Reports Q3 Financial Results and Operational Progress

Company's net loss for the nine months ended September 30, 2023, stands at $578.4 million, largely due to in-process research and development expenses

Yahoo | November 7, 2023

Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2023

MENLO PARK, Calif., November 07, 2023--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational progress for the third quarter and nine months ended September 30, 2023.

Yahoo | November 7, 2023

Laura Chow, MD, Cancer Immunotherapy Trailblazer, Joins Summit as Senior Vice President of Clinical Development

MENLO PARK, Calif., November 02, 2023--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that Laura Chow, MD, has joined Summit Therapeutics as Senior Vice President of Clinical Development.

Yahoo | November 2, 2023

Read More 'SMMT' Stories Here

SMMT Price Returns

1-mo -20.56%
3-mo N/A
6-mo 81.68%
1-year 133.76%
3-year -34.46%
5-year 81.68%
YTD 40.61%
2023 -38.59%
2022 57.99%
2021 -42.77%
2020 193.75%
2019 39.13%

Continue Researching SMMT

Here are a few links from around the web to help you further your research on Summit Therapeutics plc's stock as an investment opportunity:

Summit Therapeutics plc (SMMT) Stock Price | Nasdaq
Summit Therapeutics plc (SMMT) Stock Quote, History and News - Yahoo Finance
Summit Therapeutics plc (SMMT) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!